TOP ＞ プレナリーレクチャー

プレナリーレクチャー 7月6日（木）　11:10-12:10　Room A 1PL①-1 アルツハイマー病の疾患修飾療法をめざして Toward disease-modifying therapies of Alzheimer's disease 岩坪　威 東京大学　大学院医学系研究科　神経病理学 Takeshi Iwatsubo Dept. of Neuropathology, The University of Tokyo Disease-modifying therapies (DMT) for Alzheimer’s disease (AD) have recently been tested in clinical trials, underscoring the needs for early intervention. Positive outcomes of the recent DMT trials for anti-amyloid-β (Aβ) antibody drugs, e.g., lecanemab and donanemab, have largely depended on PET molecular imaging and fluid biomarkers that surrogate the clinical and pathophysiological progression of AD. Longitudinal observational studies as represented by AD Neuroimaging Initiative (ADNI) have paved the way towards the goal of very early treatment at the prodromal and preclinical (i.e., asymptomatic) AD stages by delineating the early natural course of AD. J-ADNI has demonstrated that the clinical and biomarker profiles of prodromal AD were remarkably similar between the Japanese and Caucasian populations, supporting the harmonization in global clinical trials. Furthermore, to enable secondary prevention trials in preclinical AD, the establishment of trial ready cohorts (TRC) is currently underway; Japanese TRC for preclinical and prodromal AD (J-TRC) is comprised of a webstudy followed by an on-site study, and ~25% of the participants of the latter was diagnosed as amyloid-positive. These clinical research activities, accelerated by the development and implementation of PET and fluid biomarkers, will facilitate the development of AD DMTs targeting its very early stages. 7月7日（金）　14:50-15:50　Room A 2PL①-1 マインド、ザ、ギャップ：脳神経疾患のより良き臨床と研究のための学際的アプローチを立ち上げる努力 Mind the gap: an effort of establishing an interdisciplinary approach for better clinical practice and research. 澤　明 ジョンズ・ホプキンス大学統合失調症疾患センター Sawa Akira Johns Hopkins University School of Medicine Johns Hopkins University Bloomberg School of Public Health Johns Hopkins Hospital and Medical Institutions Biological understanding of brain disorders is rapidly advancing in these days. This science advancement casts questions on classic nosology in psychiatry and urges us to recapture psychiatric and neurological conditions in a dimensional framework. In this presentation, from a viewpoint of biological psychiatry, I plan to introduce an effort of establishing an interdisciplinary approach for brain disorders. 7月8日（土）　10:40-11:40　Room A 3PL①-1 分析計測および医用機器による脳・神経科学への貢献 Contribution of Analytical, Measuring and Medical Instruments to Brain and Neural Science 田中　耕一 株式会社島津製作所 Tanaka Koichi Shimadzu Corporation Analytical, measuring and medical instruments are tools for observing various biological activities and the state and composition of substances by analyzing elements/compounds, and using electromagnetic waves, including X-rays and ultraviolet light. Although the contribution of these techniques to neuroscience has made remarkable progress in recent years, many parts of the brain and nervous system remain unexplored. In order to extend healthy life expectancy, in particular, it is necessary not only to make scientific progress but also to drastically change our social systems. In this talk, I will focus on the progress being made in understanding the mechanisms of the brain using mass spectrometry (MS).